The EMCDDA have published a paper on the research into drugs taking place in Europe. A couple of quotes stand out.
First on the difference between what nations say is their priority and where they’re investing in research:
Bühringer et al. (2009) found a considerable difference between the identified national research priorities and the number of studies available, particularly in the areas of ‘supply reduction’ and ‘policy’, which seemed to be relatively under-researched, or for which findings were not available. Under ‘demand reduction’, prevention was the least-researched area, although most countries considered it to be a national priority.
The second is around the new societies that are being set up on a pan-European basis, including the European Society for Prevention Research:
[The societies] may prove to be a way forward for overcoming limitations and gaps in drug-related research, further disseminate research findings, and influence priorities and the allocation of funding.